← Xeris Biopharma Holdings, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net income (loss) | ($91.1m) |
($122.7m)
-34.66%
|
($94.7m)
+22.87%
|
($62.3m)
+34.23%
|
($54.8m)
+11.92%
|
$554k
+101.01%
|
— | |
| Depreciation | $1.5m | $1.3m | $1.4m | $1.5m | $1.2m | $1.3m | $2.0m | |
| Amortization of intangible assets | $0 | $550k | $10.8m | $10.8m | $10.8m | $10.8m | — | |
| Amortization of premium/discount on investments | ($84k) | ($413k) | ($184k) | ($1.3m) | ($747k) | $0 | — | |
| Amortization of debt discount and debt issuance costs | $980k | $961k | $1.6m | $2.2m | $3.0m | $3.4m | — | |
| Amortization of operating right-of-use assets | — | $0 | $426k | $830k | $555k | $537k | — | |
| Deferred income tax expense (benefit) | — | $0 | ($1.4m) | ($1.2m) | ($2.3m) | $0 | ($3.3m) | |
| Stock-based compensation | $8.3m | $11.4m | $12.2m | $10.7m | $18.4m | $22.4m | $28.1m | |
| Trade accounts receivable | $2.2m | $6.2m | $13.4m | ($8.4m) | ($1.2m) | ($10.6m) | — | |
| Inventory | $5.1m | $7.4m | $7.5m | ($14.8m) | ($8.8m) | ($19.3m) | ($16.7m) | |
| Accounts payable | ($2.5m) | $5.5m | ($4.3m) | $7.0m | ($9.6m) | ($69k) | $4.8m | |
| Other accrued liabilities | ($2.2m) | $12.6m | ($11.4m) | ($5.9m) | $3.6m | $3.3m | — | |
| Accrued trade discounts and rebates | $4.6m | $4.2m | $1.8m | $5.3m | $3.9m | $16.4m | — | |
| Accrued returns reserve | $932k | $1.1m | $7.2m | $3.0m | $4.9m | ($113k) | — | |
| Other | $3.2m | ($1.4m) | $2.5m | $3.4m | ($1.1m) | $3.7m | — | |
| Prepaid expenses and other current assets | ($925k) | ($3.3m) | $3.9m | $3.2m | ($1.7m) | ($2.1m) | — | |
| Restricted cash included in Other assets (1) | — | $0 | $4.3m | $4.2m | $4.1m | $4.0m | — | |
| Net cash provided by (used in) operating activities | ($80.6m) |
($95.5m)
-18.59%
|
($102.9m)
-7.70%
|
($47.0m)
+54.30%
|
($37.0m)
+21.36%
|
$28.6m
+177.41%
|
$56.6m
+97.75%
|
|
| Capital expenditures | $377k | $1.1m | ($524k) | ($2.3m) | ($868k) | ($696k) | ($938k) | |
| Purchases of investments | ($101.8m) | ($43.0m) | $0 | ($43.7m) | ($34.5m) | $0 | — | |
| Sales and maturities of investments | $74.7m | $103.6m | $35.0m | $40.0m | $40.2m | $0 | — | |
| Net cash provided by (used in) investing activities | ($27.4m) | $98.0m | $34.5m | ($6.0m) | $4.9m | ($696k) | ($938k) | |
| Loss on debt extinguishment, net | ($443k) | $0 | ($1.2m) | $2.8m | $0 | $0 | — | |
| Proceeds from debt refinancing | — | — | $0 | $0 | $50.0m | $0 | — | |
| Payment of debt discount | — | — | $0 | $0 | ($11.8m) | $0 | — | |
| Payments of debt issuance costs | $5.6m | $0 | $4.9m | ($1.2m) | $0 | $0 | — | |
| Issuance of common shares in partial settlement of 2025 Convertible Debt | — | — | — | $0 | $0 | $15.1m | — | |
| Repurchase of common stock withheld for taxes | $63k | $534k | $468k | ($1.0m) | ($3.7m) | ($10.9m) | — | |
| Net cash provided by (used in) financing activities | $126.1m |
$27.2m
-78.39%
|
$127.5m
+367.84%
|
($1.6m)
-101.27%
|
$36.2m
+2342.28%
|
$11.4m
-68.51%
|
$6.7m
-41.26%
|
|
| Cash, cash equivalents and restricted cash, beginning of year | — | $67.3m | $126.3m | $71.7m | $75.7m | $115.1m | — | |
| Net cash provided by (used in) in cash, cash equivalents and restricted cash | — | $29.7m | $59.0m | ($54.6m) | $4.1m | $39.3m | — | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Change in fair value of contingent value rights | — | $0 | $3.2m | ($5.2m) | ($4.4m) | $0 | — | |
| Increase (Decrease) In Supply Agreement Liabilities | — | $0 | ($5.3m) | ($6.7m) | $0 | $0 | — | |
| Operating lease liabilities | — | $0 | ($899k) | $7.5m | $1.1m | ($1.6m) | — | |
| Proceeds from issuance of employee stock purchase plan shares | $669k | $642k | $828k | $549k | $1.2m | $1.5m | — | |
| Proceeds from exercise of stock options | $135k | $193k | $8k | $32k | $489k | $11.6m | — | |
| Proceeds from Issuance of Warrants | — | — | — | $0 | $0 | $9.2m | — | |
| Cash paid for interest | $4.6m | $7.3m | $10.9m | $27.7m | $26.9m | $27.1m | — | |
| Issuance of common shares in settlement of CVR liability | — | — | $0 | $0 | $15.8m | $0 | — | |
| Issuance of convertible note | — | $0 | $0 | $33.6m | $0 | $0 | — | |
| Cash and cash equivalents | $37.6m | $67.3m | $122.0m | $67.4m | $71.6m | $111.0m | $63.4m |